Mylan’s Biosimilars Close In On $1bn Milestone
Firm Reveals Annual Sales Total From Biosimilars Business
Mylan says it is closing in on $1bn in cumulative sales of its biosimilars, also disclosing its annual turnover figure from biosimilars as it reported its second-quarter results.
You may also be interested in...
Biocon Pays $3.3bn For Viatris Biosimilars Business
Biocon Biologics will pay up to $3.3bn to acquire the global biosimilars business of Viatris, in a long-rumored deal that will create a vertically-integrated biosimilars giant with annual sales approaching $1bn.
Viatris’ Insulin Aspart Endorsed By EMA
Viatris has received a positive opinion from the EMA’s CHMP recommending granting a pan-European marketing authorization for the firm’s insulin aspart biosimilar rival to NovoRapid.
Mylan And Biocon Launch Semglee Insulin Glargine In US
Mylan and Biocon have launched their Semglee version of insulin glargine in the US, revealing pricing details for the Lantus rival. At the same time, the firms have offered an update on their attempts to have Semglee classified as a biosimilar as they seek an interchangeability designation.